P000000	['resistant', 'advanced', 'locally advanced', 'non-metastatic', 'metastatic', 'unresectable', 'relapsed', 'relapse', 'relapsing', 'refractory', 'advanced', 'localised', 'localized', 'measurable', 'advanced', 'advanced', 'recurrent', 'newly diagnosed', 'operable', 'inoperable', 'resectable', 'no distant metastatic', 'distant metastatic', 'high risk', 'low risk', 'intermediate risk', 'resected', 'poor risk', 'high grade', 'low grade', 'intermediate grade', 'extensive stage', 'any stage', 'advanced stage', 'early stage']
P0000002	['first line', 'second line', 'third line', 'fourth line', 'fifth line', 'sixth line', 'seventh line', 'eighth line', 'ninth line', 'first line therapy', 'second line therapy', 'third line therapy', 'fourth line therapy', 'fifth line therapy', 'sixth line therapy', 'seventh line therapy', 'eighth line therapy', 'ninth line therapy', 'first line treatment', 'second line treatment', 'third line treatment', 'fourth line treatment', 'fifth line treatment', 'sixth line treatment', 'seventh line treatment', 'eighth line treatment', 'ninth line treatment', 'first line therapies', 'second line therapies', 'third line therapies', 'fourth line therapies', 'fifth line therapies', 'sixth line therapies', 'seventh line therapies', 'eighth line therapies', 'ninth line therapies', 'relapsed', 'relapse', 'relapsing', 'refractory', 'neoadjuvant therapy', 'neoadjuvant', 'adjuvant therapy', 'adjuvant', 'adjuvant endocrine therapy', 'adjuvant endocrine', 'adjuvant initial therapy', 'adjuvant extended therapy', 'induction therapy', 'initial therapy', 'initial endocrine therapy', 'extended endocrine therapy', 'consolidation therapy', 'maintenance therapy', 'second-line and above therapy', 'follow-up therapy', 'other therapy', 'last-line therapy', 'palliative therapy', 'relapse therapy', 'salvage therapy', 'preventive therapy', 'neoadjuvant therapies', 'adjuvant therapies', 'adjuvant endocrine therapies', 'adjuvant initial therapies', 'adjuvant extended therapies', 'induction therapies', 'initial therapies', 'initial endocrine therapies', 'extended endocrine therapies', 'consolidation therapies', 'maintenance therapies', 'second-line and above therapies', 'follow-up therapies', 'other therapies', 'last-line therapies', 'palliative therapies', 'relapse therapies', 'salvage therapies', 'preventive therapies', 'neoadjuvant treatment', 'adjuvant treatment', 'adjuvant endocrine treatment', 'adjuvant initial treatment', 'adjuvant extended treatment', 'induction treatment', 'initial treatment', 'initial endocrine treatment', 'extended endocrine treatment', 'consolidation treatment', 'maintenance treatment', 'second-line and above treatment', 'follow-up treatment', 'other treatment', 'last-line treatment', 'palliative treatment', 'relapse treatment', 'salvage treatment', 'preventive treatment']
P0000003	['≥18 years', 'young', ' old', ' adult', ' adults', ' childhood', ' child', ' children', ' women', ' untreated', ' pretreated', ' no prior therapy', ' male', ' female', ' postmenopausal', ' menopause', ' treatment naive', 'united states', ' american', ' north american', 'south american', 'china', ' chinese', ' japan', ' japanese', ' germany', ' german', ' united kingdom', ' british', ' india', ' indian', ' france', ' french', ' italy', ' italian', ' canada', ' canadian', ' korea', ' korean', ' brazil', ' brazilian', ' australia', ' australian', ' mexico', ' mexican', ' asian', ' european', ' african', 'newly diagnosed']
P0000004	['EGFR (S492R)', 'ERBB2 oncogenic mutation', 'KIT (627-664,664-714,449-514)', 'ABL1 (T315I)', 'BRAF (Y472C)', 'BCL6 positive', 'SLC29A1 oncogenic mutation', 'KIT mutation in exon 11', 'AR amplification', 'CHEK2 deletion', 'KIT mutation in exon 17', 'HER2 positive (HR negative)', 'PD-L1 expression＜1%', 'FGFR2 fusion', 'PDGFRA (P577S,R841K,H845Y,G853D)', 'NRAS oncogenic mutation', 'KIT (D816V)', 'IGF-1R expression', 'NTRK3 fusion', 'FLT1 overexpression', 'NTRK1 (G595R,G667C)', 'BRCA2 germline mutation', 'MDM2 amplification', 'ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)', 'FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A)', 'ERBB2 expression', 'HDAC expression', 'KIT mutation in exon 9 or 11', 'KRAS oncogenic mutation', 'FGFR3-TACC3 fusion', 'AR-V7 positive', 'MPL (W515F)', 'MAP2K1 (P124)', 'IGF-1 expression', 'KRAS mutation', 'AKT1 (Q79K,E17K)', 'NTRK1 fusion', 'TBX21 overexpression', 'PIK3CB oncogenic mutation', 'BCOR oncogenic mutation', 'NOTCH1 oncogenic mutation', 'MYC overexpression', 'PIK expression', 'FLCN deletion', 'JAK3 (R657Q,I87T,Q501H)', 'LRP1B deletion', 'PIK3R2 (A171V,N561D)', 'PD-L1 expression1%-49%', 'TPMT biallelic inactivation', 'BRAF (K601R,L597R,V600R)', 'XPO1 positive', 'MCL1 amplification', 'ALK (G1123S)', 'MET mutation in exon 16-19', 'NF2 deletion', 'BRAF G466V mutation', 'RAF1 overexpression', 'ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)', 'MYC amplification', 'IGF-1R activation', 'CD274 overexpression', 'EGFR mutation', 'EGFR exon 20 insertion', 'TP53 wildtype', 'FGFR1 amplification', 'EGFR exon 19 deletion', 'ERCC2 oncogenic mutation', 'KIT (A829P,V654A,T670I)', 'FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)', 'PDL1 overexpression', 'AR overexpression', 'PIK3CB (D1067Y)', 'MET (H1112R)', 'FGFR1 amplification', 'ALK rearrangement', 'EGFR exon 19 deletion', 'PIK3C3 mutation', 'MET exon 14 skipping mutations', 'KIT (D816Y,D816F,D816V)', 'EGFR L858R/T790M mutation', 'BAP1 deletion', 'HGF amplification', 'ROS1 negative', 'SMARCA1 oncogenic mutation', 'CHD4 overexpression', 'DNMT3A oncogenic mutation', 'dMMR', 'PBRM1 oncogenic mutation', 'KIT mutation in exon 9 or 17', 'KIT (H697Y)', 'BCL2 amplification', 'EGFR overexpression', 'EGFR-A763_Y764insFQEA', 'DDR positive', 'FGFR3 overexpression', 'TPMT splice acceptor variant', 'BCL2 overexpression', 'SH2B3 deletion', 'FGFR2 inframe insertion (A266),inframe insertion (S267)', 'FGFR3 (S249C,G691R)', 'MTOR (F2108L)', 'disialoganglioside GD2 positive', 'MET (Y1230C;Y1235D)', 'ERBB2 overexpression', 'mTOR mutation', 'MET (V1110I,H1112R,M1268T,R988C,T1010I)', 'TMPRSS2 fusion', 'ALK (L1196M)', 'EGFR-RAD51 fusion', 'TP53 oncogenic mutation', 'KIT amplification', 'FAT1 oncogenic mutation', 'PDGFRA D842V mutation', 'ANXA1 overexpression', 'BRAF (V600R)', 'KIT (D820Y)', 'CD19 mutation', 'EGFR (A289V,R108K,G598V,T263P)', 'BCL2 positive', 'BRAF (V600D,V600K,V600M,V600G,V600R)', 'KRAS wild-type', 'BRAF (V600E,G469A)', 'SRSF2 oncogenic mutation', 'FGFR3 (Y373C)', 'ERBB3 (G284R,R103G)', 'EGFR exon 20 insertion', 'ALK mutation', 'PALB2 oncogenic mutation', 'CCNE1 amplification', 'RAD51C oncogenic mutation', 'tumor mutation burden', 'NKX2-1 amplification', 'GNA11 (Q209L,Q209P)', 'CSF3R frameshift variant (D771),frameshift variant (S783)', 'EML4-ALK fusion', 'dMMR deletion', 'LRP1B oncogenic mutation', 'HER2 overexpression', 'NF2 oncogenic mutation', 'KCNJ5 (L168R)', 'G6PD overexpression', 'CCND1 amplification', 'EGFR (V843I) mutation', 'CCND1 amplification', 'MTOR (I1973F)', 'CDK12 oncogenic mutation', 'NOTCH1 fusion', 'MAP2K1 (Q56P,P124S,P124L)', 'KRAS (G12)', 'PARP expression', 'MKI67 overexpression', 'EPHA2 (G391R)', 'NRAS (G12C)', 'MDM4 amplification', 'ERCC1 oncogenic mutation', 'AURKA amplification', 'TOP2A amplification', 'CRBN (Q100*,R283K)', 'PBRM1 deletion', 'ALK positive', 'AKT3 fusion', 'RET rearrangement', 'KRAS (G13D)', 'PDGFRA fusion', 'AR (L702H,T878A)', 'KIT (550-592,627-664,788-828,829-860)', 'IL7R inframe deletion (237-255)', 'IDH2 (R140K,R172K)', 'TSC1 deletion', 'BRAF oncogenic mutation', 'MAP2K1 F129L mutation', 'TP53 (R248Q,R175H)', 'BRCA1 germline mutation', 'ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)', 'CYP17A1 expression', 'CDK6 amplification', 'EGFR oncogenic mutation', 'PTPRD oncogenic mutation', 'PAX5 mutation', 'HER2D16 positive', 'hTERT overexpression', 'ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)', 'PD-L1 expression≥50%', 'MET (D1246V)', 'ERBB2 (T798I)', 'IDH1 oncogenic mutation', 'ERBB2 (G776L)', 'EGFR (S7681,L861Q,G719X)', 'CRLF2 fusion', 'EGFR (L718)', 'EGFR L858R/T790M mutation', 'ESR1 oncogenic mutation', 'STK11 deletion', 'BRAF (D594G,G469E)', 'EGFR (S464L,G465R,I491M)', 'Chr t(11;14)  mutation', 'BRCA2 oncogenic mutation', 'ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe\\ninsertion (G776YVMA)', 'c-MET overexpression', 'IGF1R activation', 'SMARCB1 oncogenic mutation', 'AR expression', 'EGFR (D761Y)', 'FGFR expression', 'Chr del(13q)', 'HER2 negative', 'EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)', 'TSC2 deletion', 'RET (618,620,634,768,791,891,918,C634W,M918T)', 'FLT3 (D835,Y842)', 'SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)', 'AKT1 (H238Y)', 'TUBB3 overexpression', 'SERPINB3 oncogenic mutation', 'MAP2K1 (K57T)', 'SMO (P641A)', 'triple negative', 'BRCA1 oncogenic mutation', 'IGF1R amplification', 'high level MET amplification', 'PDGFRA (V658A,P577S,R841K,H845Y,G853D)', 'NRAS (Q61)', 'Luminal A', 'PD-L1 positive', 'FGFR4 (N535,V550)', 'PDGFRA (D842V)', 'HIF1A overexpression', 'PALB2 deletion', 'PLCG2 (R665W,L845F)', 'DPYD splice donor variant', 'del(17p)/TP53 mutation', 'MET (H1112L)', 'FRS2 amplification', 'RB1 expression', 'MAP2K1 (E203K,Q56P,K57E)', 'MAP2K1 oncogenic mutation', 'ALK oncogenic mutation', 'CA9 overexpression', 'BRD4-C15orf55 fusion', 'CCND1 expression', 'ALK (C1156Y)', 'KIT (788-828,829-860,550-592)', 'CBL (Y371H,C384R)', 'IRS1 activation', 'GNAQ G48V mutation', 'FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)', 'BRAF inframe deletion (L485),inframe deletion (P490)', 'MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)', 'ALK (I1171N)', 'AR (T878A)', 'JAK1 (S646F;R683)', 'KIT (N822K)', 'ALK (E1408V)', 'HYAL4-V1 expression', 'ESR1 overexpression', 'EGFR (L792)', 'EGFR (S720) mutation', 'without del(17p)/TP53 mutation', 'BTK expression', 'POLE (268-471)', 'IGF-2 expression', 'JAK2 oncogenic mutation', 'SF3B1 (K700E,K666N)', 'GNAQ (Q209)', 'FGF4 amplification', 'RB1 overexpression', 'c-KIT positive', 'CDK4 oncogenic mutation', 'BAP1 oncogenic mutation', 'KRAS G12C mutation', 'MAP2K2 (V35M,L46F,N126D,C125S)', 'CYSLTR2 L129Q mutation', 'PIK3CA mutation + HER2 positive', 'EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)', 'STK11 (D194E)', 'G6PD (V98M)', 'RB1 oncogenic mutation', 'CD69 undexpression', 'ERBB2 proximal exon 20', 'MLL fusion', 'MET exon14 alteration', 'ATR oncogenic mutation', 'SH2B3 oncogenic mutation', 'DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)', 'ERBB4 S774G mutation', 'PML-RARA fusion', 'FGFR3 oncogenic mutation', 'EGFRC797S/L798I mutation', 'MAP2K1 (P124L,K57N,C121S)', 'ERCC6 oncogenic mutation', 'HER2 positive', 'EGFR (L858R)', 'ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)', 'GATA3 oncogenic mutation', 'NF1 mutation', 'FGFR3 deletion', 'MGMT promoter methylation', 'CDKN1A oncogenic mutation', 'PDGFRA amplification', 'kRAS G12V mutation', 'EREG amplification', 'ROS1 fusion', 'CCND1 expression', 'MTOR (Q2223K)', 'AREG amplification', 'UGT1A1 (G71R,P229Q)', 'ARAF (S214C)', 'PBRM1 undexpression', 'EGFR-KDD positive', 'EGFR-C797S mutation', 'FGFR2 (W290C,S320C,K660N)', 'ARID1A oncogenic mutation', 'SETD2 oncogenic mutation', 'ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)', 'BRAF (V600E,V600K)', 'BCL-XL underexpression', 'PLK1 expression', 'AR positive', 'CD58 mutation', 'SMARCA4 deletion', 'PTEN oncogenic mutation', 'NFKBIA amplification', 'TPMT (A80P,Y240C,A154T,A167G)', 'SMARCB1 deletion', 'BRAF (V600)', 'CCND1 deletion', 'ERCC4 oncogenic mutation', 'GLI2 amplification', 'MAP2K1 (P124S,I111S)', 'IGF-1R activation', 'CDK12 amplification', 'AR negative', 'PSMA positive', 'ESR1-YAP1 fusion', 'MAP2K1 (Q56P)', 'HASPIN expression', 'ERBB2 (V659E)', 'TRK fusion', 'RET mutation', 'JAK3 (A572V,A573V)', 'CDK4 amplification', 'BRCA2 deletion', 'UGT1A1 biallelic inactivation', 'ERBB2 amplification', 'ALK (L1198F)', 'FANCC oncogenic mutation', 'APC oncogenic mutation', 'NPM1 oncogenic mutation', 'EGFR (L798I)', 'gBRCA1/2 mutation', 'ERBB4 fusion', 'PTEN deletion', 'MAP2K1 (F129L,L215P,I103N,P124)', 'TSC2 (Q1178*)', 'EGFR amplification', 'SMO (D473H)', 'CDH1 oncogenic mutation', 'MAP2K1 (Q56P,P124S,P124L;C121S)', 'VEGF positive', 'HGF overexpression', 'ERBB3 (P262H,G284R)', 'IGHV mutation', 'SETD2 deletion', 'B2M oncogenic mutation', 'SLC44A4 overexpression', 'HER2 amplification', 'VEGF expression', 'ROS1 (G2032R)', 'ERBB3 (P262H,G284R,Q809R)', 'PDGFRA inframe deletion (I843)', 'G6PD biallelic inactivation', 'AR (F877L)', 'CDCA3 overexpression', 'MAP2K1 (C121S)', 'CDKN2C deletion', 'FGFR2 amplification', 'EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)', 'G6PD (N156D)', 'PDGFRA (552-596,631-668,814-854)', 'EGFR (P546S)', 'RNF43 oncogenic mutation', 'ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)', 'CDKN2C oncogenic mutation', 'GATA3 mutation', 'HER2 mutation', 'MYC positive', 'EGFR exon 19 mutation', 'EGFR inframe insertion (769-770)', 'PAK1 amplification', 'ALK-TKI resistance mutations', 'FGFR2 (V565I)', 'SOCS1 mutation', 'ARID1A amplification', 'BRAF (V600E,V600D,V600K,V600M,V600G,V600R)', 'RAC1 (P29S) oncogenic mutation', 'FANCC deletion', 'GNAS (R201)', 'ALK inframe insertion (1151T)', 'NRG1 fusion', 'PRKCH amplification', 'ER positive', 'HER2 expression and RAS wildtype', 'ESR1 (Y537S)', 'ALK (C1156Y,L1196M)', 'BRCA1 deletion', 'PIK3CA mutation', 'NF1 biallelic inactivation', 'DPYD (I560S,D949V)', 'GRB2 expression', 'MITF amplification', 'ALK G1202R mutation', 'NTRK fusion', 'CDKN1A deletion', 'MLL2 oncogenic mutation', 'BTK (C481)', 'CDKN2B oncogenic mutation', 'RB1 deletion', 'ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)', 'EGFR inframe deletion (6-273)', 'JAK2 (V617F)', 'CDK4 amplification', 'FMS-liketyrosine kinease 3-internal tandem duplication', 'RET (I788N)', 'KIT mutation in exon 17 or 18', 'KIT exon 9 mutation', 'EGFR (E690K)', 'KIT (Y553N)', 'ATR deletion', 'mTOR L1433S mutation', 'FGF3 amplification', 'CDKN1B oncogenic mutation', 'FGFR3 mRNA overexpression', 'PI3K activation', 'CREBBP mutation', 'IDH1 (R132)', 'TSC2 oncogenic mutation', 'ERBB2 (K753E)', 'SUZ12 deletion', 'IGF-2 activation', 'NOTCH2 fusion', 'PTEN biallelic inactivation', 'ERBB2 (S310,L755,V777)', 'EGFR C797S mutation', 'FLCN oncogenic mutation', 'IDH1 mutation', 'EGFR exon 19 insertion', 'ALK (I1171T)', 'ERBB4 (H809G)', 'PIK3CA amplification', 'GnRH receptor positive', 'ERBB4 (E317K,E452K,R544W,R393W,E872K)', 'HRR mutation', 'NTRK3 (G623R)', 'MYCN amplification', 'ARAF oncogenic mutation', 'PTEN oncogenic mutation', 'CDKN2A oncogenic mutation', 'ATM biallelic inactivation', 'ALK fusion', 'ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)', 'CSF1R (Y571D)', 'BCL6 overexpression', 'RET fusion-positive', 'FGFR positive', 'CHEK2 oncogenic mutation', 'HER2 positive (HR positive)', 'AR (F877L) + AR (T878A)', 'NTRK1 (G595R)', 'EPHA2 amplification', 'HDAC2 biallelic inactivation', 'PDGFRA (T674I)', 'SETD2 mutation', 'POLE oncogenic mutation', 'MCM4 overexpression', 'BRAF (G466V)', 'FLT3 (F691,D835,N676,Y842)', 'BRAF V600E mutation', 'KIF5B-EGFR fusion', 'PDGFB-COL1A1 fusion', 'EGFR (P753S)', 'PDGFRA-FIP1L1 fusion', 'RET (C634W,M918T)', 'KIT wildtype', 'ROS1 (S1986Y,S1986F)', 'FLT3 (N676)', 'IRF8 underexpression', 'BRAF V600E mutation', 'ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)', 'PR positive', 'NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop\\nlost (2245-2536),frameshift variant (2245-2536)', 'EGFR inframe insertion (P753PS)', 'RAD50 (L1237F)', 'FOXA1 amplification', 'KDR (A1065T)', 'CXCR4 expression', 'KIT inframe deletion (577-579)', 'ALK negative', 'FGFR3 (K650)', 'ALK (F1174L)', 'PDPK1 amplification', 'VEGFA amplification', 'EML4-ALK fusion', 'BRAF (L597R)', 'KIT inframe deletion (V560)', 'CRBN expression', 'U2AF1 oncogenic mutation', 'high microsatellite instability (MSI-H)/mismatch repair deficient (dMMR)', 'KRAS amplification', 'PTCH1 oncogenic mutation', 'PDGFRA overexpression', 'ZBTB16 undexpression', 'ERCC1 deletion', 'KIT (T670I)', 'EGFR T790M mutation', 'FBXW7 oncogenic mutation', 'KRAS (12,13)', 'MET fusion', 'BRCA mutation', 'RAF1 (S257P,G361A,P261P)', 'disialoganglioside GD2 positive', 'EGFR exon 21 L858R mutation', 'EPHA3 amplification', 'GNAQ R183Q mutation', 'low expression of MMP9', 'MTOR (L1460P,S2215Y,R2505P)', 'INPP4B deletion', 'EGFR (S492R,G465R,R451C,K467T)', 'FGFR2 (S252W,N550K)', 'ERCC1 overexpression', 'JAK activation', 'ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)', 'DPYD biallelic inactivation', 'EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)', 'PTPRD mutation', 'PD-L1 expression≥20%', 'ERBB2 (V659E,S310F)', 'MTOR (E2014K,E2419K,N1421D)', 'STAG2 oncogenic mutation', 'Chr del(11q)', 'SMARCA4 oncogenic mutation', 'CTNNB1 oncogenic mutation', 'CDKN2A deletion', 'IDH2 oncogenic mutation', 'CREBBP mutation', 'BTK (C481S)', 'NF1 (D1644A)', 'JAK2 amplification', 'MSH3 oncogenic mutation', 'GATA3 overexpression', 'JAK2-BRAF fusion', 'PIK3R1 mutation', 'CDK6 oncogenic mutation', 'DDR positive', 'PI3K3CA', 'NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)', 'FBXW7 deletion', 'ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)', 'BRAF fusion', 'ALK (L1196M,S1206Y,G1269A,I1171T)', 'Luminal B (HER2 negative)', 'EGFR inframe deletion (L747)', 'Mcl-1 overexpression', 'TSC2 (E66K)', 'ALK G1269A mutation', 'ABL1 (V299L)', 'ZNRF3 oncogenic mutation', 'MYD88 (L265P)', 'EGFR (L858R,L861,G719,S768I)', 'EZH2 mutation', 'NRAS (12,13,59,61,117,146)', 'PIK3CA (E545*)', 'NF1 oncogenic mutation', 'EGFR (K757R,E746G)', 'CTNNB1 (H36Y,S37C,S37Y,D32V)', 'MAP2K1 inframe deletion (56-60)', 'CCND2 amplification', 'FANCA deletion', 'IGF-1 activation', 'EP300 mutation', 'KIT (D820E)', 'CD274 amplification', 'ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)', 'KIT mutation in exon 9,11,13,14 or 17', 'ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)', 'AKT2 amplification', 'NOTCH1 activating mutation in Cterm-PEST domain', 'SYK amplification', 'FGFR3 (V555M)', 'FGFR3 fusion', 'TSC1 oncogenic mutation', 'BRAF (L485W)', 'KRAS (12,13,59,61,117,146)', 'CCND3 amplification', 'ERBB2 (L869R)', 'FGFR fusion', 'MTOR (N1421D)', 'PLEKHM2-ALK fusion', 'VHL oncogenic mutation', 'MET kinase domain mutation', 'MAP2K2 (Q60P)', 'RICTOR amplification', 'PTPRT mutation', 'TERT promoters core', 'ROS1 rearrangement', 'EGFR (G465R)', 'BRAF (G469A)', 'TP53 deletion', 'MET amplification', 'G6PD (S218F)', 'AKT1 (E17K)', 'ERBB3 amplification', 'ITGA2 overexpression', 'FGFR1-3 expression', 'CDKN2B deletion', 'PDGFRA wildtype', 'DDR2 (S768R)', 'BRCA1 deletion', 'CYP17A1 expression', 'ERBB3 (G284R,V104M,R103G)', 'PIK3R1 oncogenic mutation', 'CREBBP inactivation', 'ALK (F856S,A348D)', 'BTK expression', 'CRBN oncogenic mutation', 'EGFR (T790M) mutation', 'MTOR (K1771R)', 'RAF1 fusion', 'ITGA2 overexpression', 'CDKN1B deletion', 'MET (M1268T)', 'FLT3 (D835)', 'KIT (D816)', 'EGFR inframe deletion (30-336)', 'HRAS oncogenic mutation', 'STK11 oncogenic mutation', 'IGF2 amplification', 'ATM deletion', 'GNAQ Q209L mutation', 'EGFR (C797S)', 'FANCA oncogenic mutation', 'RET-TPCN1 fusion', 'CREBBP inactivation', 'ABL1-BCR fusion', 'JAK1 oncogenic mutation', 'PD-L1 expression≥1%', 'KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)', 'SUZ12 oncogenic mutation', 'FLT3 mutation', 'NF1 deletion', 'IL7R inframe insertion (237-255)', 'progesterone receptor (PR) positive', 'TP53 mutation', 'ALK amplification', 'FLT3 (F691)', 'IL7R (S185C)', 'INPP4B oncogenic mutation', 'CRBN undexpression', 'MYC amplification', 'FGFR3 (K650,Y373C)', 'ERBB2/4 mutation', 'ESR1 (E380Q,537,538,L536,P535H)', 'IRF8 mutation', 'IDH2 (R172)', 'ATM oncogenic mutation', 'EZH2 (Y641,A677)', 'KIT inframe deletion (416-422),inframe insertion (416-422)', 'KIF5B-EGFR fusion']
